Published: Issue date: DOI:
The conflicting safety signal One real-world evidence study found that patients receiving GLP-1 receptor agonists had higher risks of certain autoimmune conditions, including ulcerative colitis, rheumatoid arthritis, autoimmune thyroiditis, ankylosing spondylitis, and psoriasis, compared to those on DPP-4 inhibitors
Liraglutide alters DPP4 in the circumvallate papillae of type 2 diabetic rats
Research-Grade Analytical Documentation: Each batch is supported by standard characterization (e.g., COA, HPLC data, and MS confirmation), ensuring consistency across experiments and study sites
The researchers compared exercise alone, exercise plus liraglutide, or liraglutide alone in people without diabetes
Why did they try to submit it to my insurance when it clearly states this a new GLP-1 Bridge